Page last updated: 2024-08-21

indazoles and Incontinentia Pigmenti Achromians

indazoles has been researched along with Incontinentia Pigmenti Achromians in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Altavilla, D; Cannavò, SP; Riso, G; Vaccaro, M	1
Coen, M; Cramer, B; Serratrice, J	1
Chatzidimitriou, E; Christofidou, E; Dimitrakopoulou, A; Kostaki, M; Plaka, M; Polydorou, D; Stathopoulou, A; Stratigos, A; Zaras, A	1
Robert, C; Sibaud, V	1
Kawai, A; Kawashima, M; Kobayashi, E; Kobayashi, K; Koyama, T; Setsu, N	1

Reviews

1 review(s) available for indazoles and Incontinentia Pigmenti Achromians

Article	Year
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies]. Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles	2013

Article

Year

[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].

Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles

2013

Other Studies

4 other study(ies) available for indazoles and Incontinentia Pigmenti Achromians

Article	Year
Eyelashes depigmentation following treatment with pazopanib for metastatic renal cell carcinoma. Dermatologic therapy, 2019, Volume: 32, Issue:6 Topics: Carcinoma, Renal Cell; Eyelashes; Female; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Pigmentation Disorders; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2019
[Abnormal hair]. La Revue de medecine interne, 2019, Volume: 40, Issue:2 Topics: Carcinoma, Renal Cell; Female; Hair; Hair Color; Hair Diseases; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Pigmentation Disorders; Pyrimidines; Sulfonamides	2019
Pazopanib induced pigmented lesions of the scrotum and the face in a patient with metastatic renal cancer. Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Face; Humans; Indazoles; Male; Middle Aged; Pigmentation Disorders; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Scrotum; Sulfonamides	2019
Reversible hair depigmentation in a Japanese female treated with pazopanib. The Journal of dermatology, 2014, Volume: 41, Issue:11 Topics: Adult; Bone Neoplasms; Female; Hair Diseases; Hip Joint; Humans; Indazoles; Pigmentation Disorders; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma; Sulfonamides	2014